30
Participants
Start Date
January 15, 2025
Primary Completion Date
July 15, 2026
Study Completion Date
September 15, 2026
his is a prospective, single-arm, multicentre, non-randomised phase II, pilot study designed to achieve or maintain virological success in participants who meet the prescribing criteria for lenacapavi
"cabotegravir initiation: daily oral route of 1 tablet 30 mg at Day 0 to week 4 Cabotegravir maintennace: Every 8 weeks (+/- 1 week) intramuscular injection from week 8 at week 48.~Lenacapavir initiation: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites + orale route of 2 tablets of 300mg (ie 600 mg) at Day 0 and at day 1: orale route of 2 tablets of 300mg (ie 600 mg) Lenacapavir maintenance: Subcutaneous injection (927mg/3ml),ie 2 injections of 463,5mg/1,5mL in 2 distinct abdominal sites every 24 weeks (+/-1 week) from Day 0 to Week 48"
Hopital Saint Antoine, Paris
Hopital Pitié Salpêtrière, Paris
Hopital Necker, Paris
Hopital Bichat Claude Bernard, Paris
Hopital Saint André, Bordeaux
Hopiytal Pellegrin, Bordeaux
Centre hospitalier François Mitterrand, Dijon
Hopital raymond Poincaré, Garches
Hôpital Franco-Britannique, Levallois-Perret
CHU de nantes- Hotel Dieu, Nantes
Chu- Nice Archet, Nice
Centre hospitalier de Tourcoing, Tourcoing
ANRS, Emerging Infectious Diseases
OTHER_GOV
Institut de Médecine et d'Epidémiologie Appliquée - Fondation Internationale Léon M'Ba
OTHER